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Abstract
Although transcription activator-like effector nucleases (TALENs) can be designed to cleave
chosen DNA sequences, TALENs have been shown to have activity against related off-target
sequences. To better understand TALEN specificity and engineer TALENs with improved
specificity, we profiled 30 unique TALENs with varying target sites, array length, and domain
sequences for their ability to cleave any of 1012 potential off-target DNA sequences using in vitro
selection and high-throughput sequencing. Computational analysis of the selection results
predicted 76 off-target substrates in the human genome, 16 of which were accessible and modified
by TALENs in human cells. The results collectively suggest that (i) TALE repeats bind DNA
relatively independently; (ii) longer TALENs are more tolerant of mismatches, yet are more
specific in a genomic context; and (iii) excessive DNA-binding energy can lead to reduced
TALEN specificity in cells. Based on these findings, we engineered a TALEN variant, Q3, that
exhibits equal on-target cleavage activity but 10-fold lower average off-target activity in human
cells. Our results demonstrate that identifying and mutating residues that contribute to non-specific
DNA-binding can yield genome editing reagents with improved DNA specificities.
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tIntroduction
The ability to engineer site-specific changes in genomes is a powerful capability with
significant research and therapeutic implications. Transcription activator-like effector
nucleases (TALENs) are fusions of the FokI restriction endonuclease cleavage domain with
a DNA-binding TALE repeat array (Fig. 1A). These arrays consist of multiple 34-amino
acid TALE repeat sequences, each of which uses a repeat-variable di-residue (RVD), the
amino acids at positions 12 and 13, to recognize a single DNA nucleotide.1, 2 Examples of
RVDs that recognize each of the four DNA base pairs are known, enabling arrays of TALE
repeats to be constructed that can bind virtually any DNA sequence. TALENs can be
engineered to be active only as heterodimers through the use of obligate heterodimeric FokI
variants.3, 4 In this configuration, two distinct TALEN monomers are each designed to bind
one target half-site resulting in cleavage within the DNA spacer sequence between the two
half-sites. In cells, TALEN-induced double-strand breaks can result in targeted gene
knockout through non-homologous end joining (NHEJ)5 or precise targeted genomic
sequence alteration through homology-directed repair (HDR) with an exogenous DNA
template.6, 7 TALENs have been successfully used to manipulate genomes in a variety of
organisms6, 8–11 and cell lines.5, 7, 12, 13
Although TALENs are sufficiently specific to show activity against their intended target
sites without causing widespread and highly abundant genomic off-target modification,14–17
TALEN-mediated DNA cleavage at off-target sites can result in unintended mutations at
genomic loci. While recent studies identify closely related off-target sites containing two or
fewer mismatches in zebrafish18 and in human cell lines,13 more distantly related off-target
sites are of particular interest since one would expect a typical 36-bp target site to be
approximately eight or more mutations away from any sequence in the human genome. In
previous studies, two distant genomic off-target sites were identified from 19 potential off-
target sites predicted using SELEX,7 an in vitro method to identify binding sites of DNA-
binding domains in isolation. Only a single heterodimeric off-target site was identified using
an integrase-deficient lentiviral vector(IDLV)-based approach19, 20 to capture off-target
double-strand break sites in cells. The limited number of off-target TALEN sites identified
in previous studies suggest that further research is needed both to better understand the
extent of TALEN-induced genomic off-target mutations and to improve TALEN specificity
to minimize these unwanted effects.
The underlying principles that determine the specificities of TALEN proteins remain poorly
characterized. While SELEX experiments and a high-throughput study of TALE activator
specificity have described the DNA-binding specificities of monomeric TALE proteins5, 7,9
and a single TALE activator,21 respectively, the DNA cleavage specificities of active,
dimeric nucleases can differ from the specificities of their component monomeric DNA-
binding domains.22 For example, zinc finger nucleases (ZFNs), another type of engineered
dimeric nuclease, demonstrate compensation effects between monomers.22 Cellular methods
to study off-target genomic modification such as whole-genome sequencing or IDLV
capture could be complicated by cellular factors such as DNA accessibility, which varies
from site to site and between cell types,23 or DNA repair and integration pathways after
cleavage that could obscure the determination of intrinsic TALEN protein specificity. Purely
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tcellular studies are also inherently limited to the stochastic handful of off-target sites in a
given genome that are similar to the target sequence and thus are unable to evaluate the
ability of TALENs to cleave a very large number of off-target sites necessary for a broad
and in-depth study of TALEN specificity.
Using a previously described in vitro selection method,22, 24 we interrogated TALENs for
their abilities to each cleave 1012 potential off-target DNA substrates related to their
intended target sequences. The resulting data provide the first comprehensive profiles of
TALEN cleavage specificities in a manner that is not limited to the small number of typical
target-related sites in a genome. The selection results suggest a model in which excess non-
specific DNA-binding energy gives rise to greater off-target cleavage relative to on-target
cleavage. Based on this model, we engineered TALENs with a modified architecture that
show substantially improved DNA cleavage specificity in vitro. In human cells, these
modified TALENs exhibit 24- to > 120-fold greater specificity for the most readily cleaved
off-target site than currently used TALEN constructs.
Results
Specificity Profiling of TALENs targeting the human CCR5 and ATM genes
We profiled the specificities of 30 unique heterodimeric TALEN pairs (hereafter referred to
as TALENs) harboring different C-terminal, N-terminal and FokI domain variants and
targeted to sites with half-sites of various lengths. Throughout this report, the number of
base pairs recognized by each half-site is listed to include the 5′ T nucleotide recognized by
the N-terminal domain. Most of the TALENs tested contained the obligate heterodimeric
EL/KK FokI domain, although the more active heterodimeric ELD/KKR and homodimeric
FokI nuclease domain were also used, as specified below.3, 26 TALENs were constructed as
previously reported12 and designed to target one of three distinct sequences, which we refer
to as CCR5A, CCR5B, or ATM, in two different human genes, CCR5 and ATM
(Supplementary Fig. S1). The specificity profiles were generated using a previously
described in vitro selection method.22, 24 Briefly, pre-selection libraries of > 1012 DNA
sequences each were digested with 3 nM to 40 nM of an in vitro-translated TALEN (see
Methods and Supplementary Results for more detail). The pre-selection DNA libraries were
sufficiently large that they each contain, in theory, at least ten copies of all possible DNA
sequences with six or fewer mutations relative to the on-target sequence. Cleaved library
members harbored a free 5′ monophosphate that enabled them to be captured by adapter
ligation (Fig. 1B). DNA fragments of length corresponding to 1.5 target sites (an intact
target site and a repeated half-site up to the point of TALEN-induced DNA cleavage) were
isolated by gel purification. High-throughput sequencing and computational analysis of
TALEN-treated or control samples surviving this selection process revealed the abundance
of all TALEN-cleaved sequences as well as the abundance of the corresponding sequences
before selection. In the control sample, all members of the pre-selection library were cleaved
by a restriction endonuclease at a constant sequence to enable them to be captured by
adapter ligation and isolated by gel purification. The enrichment value for each library
member surviving selection was calculated by dividing its post-selection sequence
abundance by its pre-selection abundance.
Guilinger et al. Page 3
Nat Methods. Author manuscript; available in PMC 2014 October 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFor all TALEN variants and under all tested conditions, the DNA that survived the selection
contained significantly fewer mean mutations in the targeted half-sites than were present in
the preselection libraries (Fig. 2A and 2B; Supplementary Table S2 and S3). For all
selections, the on-target sequences were enriched by 8- to 640-fold with an average
enrichment value of 110-fold (Supplementary Table S4). To validate our selection results in
vitro, we assayed the ability of the CCR5B TALEN targeting 13-bp left and right half-sites
(L13+R13) to cleave each of 16 diverse off-target substrates (Fig. 2E and 2F). The
efficiencies with which each of these 16 putative off-target substrates were cleaved by the
TALEN in these discrete in vitro assays correlated well (r = 0.90) with the observed
enrichment values from the selection (Fig. 2G).
To quantify the DNA cleavage specificity at each position in the TALEN target site for all
four possible base pairs, a specificity score was calculated as the difference between pre-
selection and post-selection base pair frequencies, normalized to the maximum possible
change of the pre-selection frequency from complete specificity (defined as 1.0) to complete
anti-specificity (defined as −1.0). For all TALENs tested, the targeted base pair at every
position in both half-sites is preferred, with the sole exception of the base pair closest to the
spacer for some ATM TALENs at the right-half site (Fig. 2C, 2D and Supplementary Fig.
S3 through S8). The 5′ T recognized by the N-terminal domain is highly specified, and the
3′ DNA end (targeted by the C-terminal TALEN end) generally tolerates more mutations
than the 5′ DNA end; both of these observations are consistent with previous reports.27, 28
All 12 of the positions targeted by the NN RVDs in the ATM and CCR5A TALENs were
enriched for G, confirming previous reports5, 7, 27, 29 that the NN RVD specifies G. Taken
together, these results show that the selection data accurately predicts the efficiency of off-
target TALEN cleavage in vitro, and that TALENs are overall quite specific across the entire
target sequence.
TALEN Off-Target Cleavage in Cells
For TALENs targeting a total of 36 base pairs, potential off-target sites in the human
genome are expected on average to contain approximately eight or more mutations relative
to the on-target site (Supplementary Table S5), more mutations than theoretically are
covered in the in vitro selection. Therefore, we used a machine-learning “classifier”
algorithm25 trained on the tens of thousands of off-target sites revealed by the in vitro
selection to identify rare TALEN candidate off-target sites in the human genome (see
Supplementary Results for details). Using this algorithm, we identified the 36 best-scoring
heterodimeric candidate off-target sites for the ATM TALENs and 48 of the best-scoring
candidate off-target sites for the CCR5A TALENs (Supplementary Table S6). These sites
differ from the on-target sequence at seven to fourteen positions.
These 84 predicted off-target sites for CCR5A and ATM TALENs were amplified from
genomic DNA purified from human U2OS-EGFP cells expressing either CCR5A or ATM
TALENs.12 Sequences containing insertions or deletions of three or more base pairs in the
DNA spacer of the potential genomic off-target sites and present in significantly greater
numbers in the TALEN-treated samples versus the untreated control sample were considered
TALEN-induced modifications. Consistent with a previous report3, CCR5A or ATM
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tTALENs containing ELD/KKR and homodimeric FokI domains demonstrated increased on-
target activity compared to EL/KK FokI domains. Of the 45 CCR5A off-target sites that we
successfully amplified, we identified nine off-target sites with TALEN-induced
modifications; likewise, of the 31 ATM off-target sites that we successfully amplified, we
observed seven off-target sites with TALEN-induced modifications (Fig. 3 and
Supplementary Table S7 and S9). Therefore, in total, 16 out of 76 assayed off-target
candidates were accessible and modified by TALENs in cells. The inspection of modified
on-target and off-target sites yielded a prevalence of deletions ranging from three to dozens
of base pairs (Supplementary Fig. S9), consistent with previously described characteristics
of TALEN-induced genomic modification.31 These results collectively indicate in vitro
selection data processed through a machine-learning algorithm, can predict bona fide off-
target substrates that undergo TALEN-induced modification in human cells. We also
directly compared our combined in vitro selection and machine learning method with
TALENoffer, a recently described purely computational prediction method32 and found that
our approach outperforms the purely computational approach for the identification of
TALEN-induced off-target substrates in cells (Supplementary Tables S8 and S9 and
Supplementary Results).
TALE Repeat Binding Independence and Effects of TALEN Length on Specificity
The extensive number of quantitatively characterized off-target substrates in the selection
data enabled us to address several key questions about TALEN specificity. First, we
assessed whether mutations at one position in the target sequence affect the ability of
TALEN repeats to productively bind other positions and concluded that TALE repeats bind
their respective DNA base pairs independently beyond a slightly increased tolerance for
adjacent mismatches (Supplementary Results).
The independent binding of TALE repeats simplistically predicts that TALEN specificity
per base pair is independent of target-site length. To experimentally characterize the
relationship between TALE array length and off-target cleavage, we constructed TALENs
targeting 10, 13, or 16 bps (including the 5′ T) for both the left (L10, L13, L16) and right
(R10, R13, R16) half-sites. TALENs representing all nine possible combinations of left and
right CCR5B TALENs were subjected to in vitro selection. The results revealed that shorter
TALENs have greater specificity per targeted base pair than longer TALENs
(Supplementary Table S2). For example, sequences cleaved by the L10+R10 TALEN
contained a mean of 0.032 mutations per recognized base pair, while those cleaved by the
L16+R16 TALEN contained a mean of 0.067 mutations per recognized base pair.
For selections with the longest CCR5B TALENs targeting 16+16 base pairs or CCR5A and
ATM TALENs targeting 18+18 bp, the mean selection enrichment values do not follow a
simple exponential decrease as function of mutation number (Fig. 4 and Supplementary
Table S10). It is possible these TALENs have greater affinity than is required to
substantially bind and cleave the target site (referred to hereafter as “excess DNA-binding
energy”). Thus, we hypothesize that excess DNA-binding energy from the larger number of
TALE repeats in longer TALENs reduces specificity by enabling the cleavage of sequences
with more mutations, without a corresponding increase in the cleavage of sequences with
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tfewer mutations, because the latter are already nearly completely cleaved. Indeed, the in
vitro cleavage efficiencies of discrete DNA sequences for these longer TALENs are
independent of the presence of a small number of mutations in the target site (Fig. 5C–5F),
suggesting there is nearly complete binding and cleavage of sequences containing few
mutations. Likewise, higher TALEN concentrations also result in decreased enrichment
values of sequences with few mutations while increasing the enrichment values of sequences
with many mutations (Supplementary Table S4). These results together support a model in
which excessive TALEN binding arising from either long TALE arrays or high TALEN
concentrations decreases the observed TALEN DNA cleavage specificity for each
recognized base pair. Despite being less specific per base pair, TALENs designed to cleave
longer target sites are estimated to have higher overall specificity than those that target
shorter sites when considering the number of potential off-target sites in the human genome
(Supplementary Results).
Engineering TALENs with Improved Specificity
The findings above suggest that TALEN specificity could be improved by reducing non-
specific DNA binding energy to only what is needed to support efficient on-target cleavage.
The most widely used 63-aa C-terminal domain between the TALE repeat array and the
FokI nuclease domain contains ten cationic residues.4, 5, 7, 9, 10, 12 A related C-terminal
domain variant (89% homology), containing 11 cationic residues, has also been used in
other studies.6, 20, 28 We hypothesized that reducing the cationic charge of the canonical 63-
aa TALE C-terminal domain would decrease non-specific DNA binding33 and improve the
specificity of TALENs.
We constructed two C-terminal domain variants in which three (“Q3”, consisting of K788Q,
R792Q, and R801Q) or seven (“Q7”, consisting of K777Q, K778Q, K788Q, R789Q,
R792Q, R793Q, and R801Q) cationic Arg or Lys residues in the canonical 63-aa C-terminal
domain were mutated to Gln. We performed in vitro selections on CCR5A and ATM
TALENs containing the canonical 63-aa, the engineered Q3, and the engineered Q7 C-
terminal domains, as well as a previously reported 28-aa truncated C-terminal domain5 with
a theoretical net charge (−1) identical to that of the Q7 C-terminal domain. The on-target
sequence enrichment values for the CCR5A and ATM selections increased substantially as
the net charge of the C-terminal domain decreased (Fig. 5A and 5B). For example, the ATM
selections resulted in on-target enrichment values of 510, 50, and 20 for the Q7, Q3, and
canonical 63-aa C-terminal variants, respectively. These results suggest that the TALEN
variants in which cationic residues in the C-terminal domain have been partially replaced by
neutral residues or completely removed are substantially more specific in vitro than the
TALENs that contain the canonical, commonly used 63-aa C-terminal domain. Similarly,
mutating one, two, or three cationic residues in the TALEN N-terminus to Gln also
increased cleavage specificity (Supplementary Table S4, and Supplementary Fig. S3–S6,
and see Supplementary Results).
In order to confirm the greater DNA cleavage specificity of Q7 over canonical 63-aa C-
terminal domains in vitro, a representative set of 16 off-target DNA substrates was digested
in vitro with TALENs containing either canonical 63-aa or engineered Q7 C-terminal
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tdomains. ATM TALENs with the canonical 63-aa C-terminal domain demonstrated
comparable in vitro cleavage activity on target sites with zero, one, or two mutations (Fig.
5C–5F). CCR5A TALENs with the canonical 63-aa C-terminal domain TALEN
demonstrate comparable in vitro cleavage activity on target sites with zero or two mutations.
In contrast, for 11 of the 16 off-target substrates tested, the engineered Q7 TALEN variants
showed substantially higher (~4-fold or greater) discrimination against off-target DNA
substrates with one or two mutations than the canonical 63-aa C-terminal domain TALENs,
even though the Q7 TALENs cleaved their respective on-target sequences in vitro with
comparable or greater efficiency than TALENs with the canonical 63-aa C-terminal domains
(Fig. 5C–5F). For both the ATM and CCR5A Q7 C-terminal TALENs, some sequences are
cleaved with greater specificity than others. Sequence-dependent specificity is expected
based on the variable specificity at each position (Fig. 2C and D). Overall, the discrete
cleavage assays are consistent with the selection results and indicate that TALENs with
engineered Q3 or Q7 C-terminal domains can be substantially more specific than TALENs
with canonical 63-aa C-terminal domains in vitro.
Improved Specificity of Engineered TALENs in Human Cells
To determine if the increased specificity of the engineered TALENs observed in vitro also
occurs in human cells, TALEN-induced modification rates of the on-target and top 36
predicted off-target sites were measured for CCR5A and ATM TALENs containing all six
possible combinations of the canonical 63-aa, Q3, or Q7 C-terminal domains and the EL/KK
or ELD/KKR FokI domains (12 TALENs total). We did not analyze TALENs containing a
28-aa C-terminal domain in these experiments because both the ATM and CCR5A on-target
sites have DNA spacer lengths of 18 bp, which lies outside the 28-aa C-terminal domain’s
preferred DNA spacer length range (Supplementary Fig. S14). For both FokI variants, the
TALENs with Q3 C-terminal domains demonstrate significant on-target activities ranging
from 8% to 24% modification, comparable to the activity of TALENs with the canonical 63-
aa C-terminal domains. TALENs with canonical 63-aa or Q3 C-terminal domains and the
ELD/KKR FokI domain are both more active in modifying the CCR5A and ATM on-target
site in cells than the corresponding TALENs with the Q7 C-terminal domain by 5- to 9-fold
(Fig. 6A–C and Supplementary Table S7).
Compared to the canonical 63-aa C-terminal domains, TALENs with Q3 C-terminal
domains demonstrate a mean increase in on-target:off-target activity ratio of more than 12-
fold and more than 9-fold for CCR5A and ATM sites, respectively, with the ELD/KKR FokI
domain (Fig. 6A–C & Supplementary Table S7). These mean improvements can only be
expressed as lower limits due to the absence or near-absence of observed cleavage events by
the engineered TALENs for many off-target sequences. For the ATM TALENs containing
Q7 C-terminal domains, the cleavage efficiency of both the on-target and off-target sites is
so low that their specificity cannot be determined (Fig. 6C). For the most abundantly
cleaved off-target site (CCR5A off-target site #5), the Q3 C-terminal domain is 24-fold
more specific, and the Q7 C-terminal domain is > 120-fold more specific (Fig. 6A), than the
canonical 63-aa C-terminal domain. Consistent with the improved on-target:off-target
activity ratio observed in vitro, the engineered Q7 TALENs are more specific than the Q3
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tvariants, which in turn are more specific than the canonical 63-aa C-terminal domain
TALENs.
To determine if the increased specificity of the engineered TALENs observed for CCR5A
and ATM TALENs applies more generally, three new TALENs targeting sequences in the
PMS2, SDHD, and HDAC1 genes12 were constructed using the canonical 63-aa, Q3, or Q7
C-terminal domains and ELD/KKR FokI domains. Of the 64 TALENs reported previously
in Reyon et al, these three TALENs had target sequences with closely homologous genomic
off-target sites containing one to five mutations. For each of these TALENs, modification
rates were measured for genomic on-target and off-target sites. PMS2, SDHD, and HDAC-1
TALENs with Q3 C-terminal domains demonstrate on-target activities ranging from 6% to
28% modification, comparable to the activity of TALENs with the canonical 63-aa C-
terminal domains (Fig. 6D and Supplementary Table S8). While demonstrating similar on-
target activities to TALENs with canonical domains, PMS2, SDHD, and HDAC1 TALENs
with Q3 C-terminal domains demonstrated a 5- to 7-fold increase in on-target:off-target
activity ratio. For the PMS2 TALENs, the Q7 C-terminal domains demonstrated a 53- and
64-fold increase in on-target:off-target activity ratio in cells, although as observed above the
Q7 TALENs were less active on the target site than TALENs containing the canonical and
Q3 C-terminal domains (Fig. 6D and Supplementary Table S8).
Together, these results reveal that for five families of TALENs targeting the CCR5, ATM,
PMS2, SDHD, and HDAC1 genes, replacing the canonical 63-aa C-terminal domain with
the engineered Q3 C-terminal domain results in comparable activity for the on-target site in
cells, and an average 10-fold increase in specificity for all assayed off-target sites. The
engineered Q7 C-terminal domain can offer additional gains in specificity beyond that of the
Q3 TALENs, but with reduced on-target activity. Collectively, these results validate a
method to evaluate the specificity of TALEN variants that also revealed underlying
principles resulting in engineered TALENs with improved DNA cleavage specificity in
cells.
Discussion
The in vitro selection results for 30 unique TALENs each challenged with 1012 closed
related off-target sequences and subsequent analysis inform our understanding of TALEN
specificity through four key findings: (i) TALENs are highly specific for their intended
target base pair at 103 of the 104 positions profiled with specificity increasing near the N-
terminal TALEN end of each TALE repeat array (corresponding to the 5′ end of the bound
DNA); (ii) longer TALENs are more specific in a genomic context while shorter TALENs
have higher specificity per nucleotide; (iii) TALE repeats each bind their respective base
pairs relatively independently; and (iv) excess DNA-binding affinity leads to increased
TALEN activity against off-target sites and therefore decreased specificity.
The 16 confirmed TALEN off-target sites containing eight to 12 mutations identified from
the 76 predicted sites assayed in this study represent more bona fide genomic off-target sites
in the human genome than have been revealed collectively to date by other methods. These
16 sites were modified at efficiencies ranging from 2.3% to 0.03% in human cells,
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tdemonstrating that TALENs can have appreciable off-target activities in human cells even at
sites that are eight or more mutations away from the on-target sequence. Site accessibility in
cells, mediated by histone proteins, transcription factors, and DNA modification,23 likely
account for at least some of the difference between our in vitro, computational, and cell-
based results. For a comparison of our method with others for characterizing TALEN
specificity and identifying genomic TALEN off-target sites, see the Supplementary
Discussion.
The observed decrease in specificity for TALENs with more TALE repeats or more cationic
residues in the C-terminal domain or N-terminus are consistent with a model in which
excess TALEN binding affinity leads to increased promiscuity. This excess binding energy
model may explain reports that NN RVDs bind either A or G.2,28,35 These studies used
TALE arrays of more than 14 RVDs, which could have created a scenario in which excess
DNA-binding energy permits a suboptimal NN RVD interaction with A compared to G. We
observed NN RVDs can discriminate between A and G, consistent with reports using shorter
TALE arrays of 13 RVDs29 and by direct biochemical interrogation.27 Excess DNA-binding
energy could also explain the previously reported promiscuity at the 5′ terminal T of
TALENs with longer C-terminal domains36 and is consistent with a report of higher TALEN
protein concentrations resulting in more off-target site cleavage in vivo.9 While decreasing
TALEN protein expression in cells in theory could reduce off-target cleavage, TALE arrays
are reported with on-target DNA binding affinities as high as Kd = 2.8 nM,27 which is
sufficient to theoretically saturate target sites even when expressed at modest, mid-nM
concentrations in the cell. The difficulty of improving the specificity of such TALENs by
lowering their expression levels, coupled with the need to maintain sufficient TALEN
concentrations to effect desired levels of on-target cleavage, highlight the value of
engineering TALENs with higher intrinsic specificity such as those described in this work.
Our findings suggest that mutant C-terminal domains with reduced non-specific DNA
binding may be used to alter the DNA-binding affinity of TALENs such that on-target
sequences are cleaved efficiently but with minimal excess DNA-binding energy, resulting in
better discrimination between on-target and off-target sites. Since TALENs targeting up to
46 total base pairs have been shown to be active in cells,14 it may be possible to further
improve specificity by engineering TALENs with a combination of mutant N-terminal and
C-terminal domains that impart reduced non-specific DNA-binding, a greater number of
TALE repeats to contribute additional on-target DNA binding, and lower-affinity RVDs
such as the NK RVD to recognize G.28, 29 It is tempting to speculate that the strategy of
mutating residues that contribute to non-specific DNA binding to improve DNA specificity
may also apply to other genome engineering proteins including Cas9 and ZFNs.
Our model and the resulting improved TALENs would have been difficult to derive or
validate using purely cellular off-target cleavage methods. The ability of our profiling
method to reveal the broad, unobscured DNA cleavage specificity of TALENs in the
absence of cellular complications enabled the elucidation of the inherent DNA-cleavage
specificity of TALENs. Studies of cellular off-target cleavage are also intrinsically limited
by the small number of sequences present in a genome that may be closely related to a target
sequence of interest. In contrast, each active, dimeric TALEN in this study was evaluated for
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tits ability to cleave any of 1012 close variants of its on-target sequence, a library size several
orders of magnitude greater than the number of different sequences in a mammalian
genome. This dense coverage of off-target sequence space enabled the elucidation of
detailed relationships between DNA-cleavage specificity and target base pair position,
TALE repeat length, TALEN concentration, mismatch location, and engineered TALEN
composition. These results collectively reveal principles for characterizing and improving
TALENs with greater specificity that may enable a wider range of genome engineering
applications.
ONLINE METHODS
Oligonucleotides, PCR and DNA Purification
All oligonucleotides were purchased from Integrated DNA Technologies (IDT).
Oligonucleotide sequences are listed in Supplementary Table S12. PCR was performed with
0.4 μL of 2 U/μL Phusion Hot Start II DNA polymerase (Thermo-Fisher) in 50 μL with 1x
HF Buffer, 0.2 mM dNTP mix (0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM
dTTP) (NEB), 0.5 μM to 1 μM of each primer and a program of: 98 °C, 1 min; 35 cycles of
[98 °C, 15 s; 62 °C, 15 s; 72 °C, 1 min] unless otherwise noted. Many DNA reactions were
purified with a QIAquick PCR Purification Kit (Qiagen) referred to below as Q-column
purification or MinElute PCR Purification Kit (Qiagen) referred to below as M-column
purification.
TALEN Construction
The canonical TALEN plasmids were constructed by the FLASH method12 with each
TALEN targeting 10–18 base pairs. N-terminal mutations were cloned by PCR with Q5 Hot
Start Master Mix (NEB) [98 °C, 22 s; 62 °C, 15 s; 72 °C, 7 min]) using phosphorylated
TAL-N1fwd (for N1), phosphorylated TAL-N2fwd (for N2), or phosphorylated TAL-N3fwd
(for N3) and phosphorylated TAL-Nrev as primers. 1 μL DpnI (NEB) was added and the
reaction was incubated at 37 °C for 30 min then M-column purified. ~25 ng of eluted DNA
was blunt-end ligated intramolecularly in 10 μL 2x Quick Ligase Buffer, 1 μL of Quick
Ligase (NEB) in a total volume of 20 μL at room temperature (~21 °C) for 15 min. 1 μL of
this ligation reaction was transformed into Top10 chemically competent cells (Invitrogen).
C-terminal domain mutations were cloned by PCR using TAL-Cifwd and TAL-Cirev
primers, then Q-column purified. ~1 ng of this eluted DNA was used as the template for
PCR with TAL-Cifwd and either TAL-Q3 (for Q3) or TAL-Q7 (for Q7) for primers, then Q-
column purified. ~1 ng of this eluted DNA was used as the template for PCR with TAL-
Cifwd and TAL-Ciirev for primers, then Q-column purified. ~1 μg of this DNA fragment
was digested with HpaI and BamHI in 1x NEBuffer 4 and cloned22 into ~2 μg of desired
TALEN plasmid pre-digested with HpaI and BamHI. TALENs containing the N-terminal
mutant domains, the Q3 C-terminal domains and the Q7 C-terminal will be available from
Addgene.
In Vitro TALEN Expression
TALEN proteins, all containing a 3xFLAG tag, were expressed by in vitro transcription/
translation. 800 ng of TALEN-encoding plasmid or no plasmid (“empty lysate” control) was
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tadded to an in vitro transcription/translation reaction using the TNT® Quick Coupled
Transcription/Translation System, T7 Variant (Promega) in a final volume of 20 μL at 30 °C
for 1.5 h. Western blots were used to visualize protein using the anti-FLAG M2 monoclonal
antibody (Sigma-Aldrich). TALEN concentrations were calculated by comparison to
standard curve of 1 ng to 16 ng N-terminally FLAG-tagged bacterial alkaline phosphatase
(Sigma-Aldrich).
In Vitro Selection for DNA Cleavage
Pre-selection libraries were prepared with 10 pmol of oligo libraries containing partially
randomized target half-site sequences (CCR5A, ATM, or CCR5B) and fully randomized 10-
to 24-bp spacer sequences (Supplementary Table S12). Oligonucleotide libraries were
separately circularized by incubation with 100 units of CircLigase II ssDNA Ligase
(Epicentre) in 1x CircLigase II Reaction Buffer (33 mM Tris-acetate, 66 mM potassium
acetate, 0.5 mM dithiothreitol, pH 7.5) supplemented with 2.5 mM MnCl2 in 20 μL total for
16 h at 60 °C then incubated at 80 °C for 10 min. 2.5 μL of each circularization reaction was
used as a substrate for rolling-circle amplification at 30 °C for 16 h in a 50-μL reaction using
the Illustra TempliPhi 100 Amplification Kit (GE Healthcare). The resulting concatemerized
libraries were quantified with Quant-iT™ PicoGreen ® dsDNA Kit (Invitrogen) and
libraries with different spacer lengths were combined in an equimolar ratio.
For selections on the CCR5B sequence libraries, 500 ng of pre-selection library was
digested for 2 h at 37 °C in 1x NEBuffer 3 with in vitro transcribed/translated TALEN plus
empty lysate (30 μL total). For all CCR5B TALENs, in vitro transcribed/translated TALEN
concentrations were quantified by Western blot (during the blot, TALENs were stored for 16
h at 4 °C) and then TALEN was added to 40 nM final concentration per monomer. For
selections on CCR5A and ATM sequence libraries, the combined pre-selection library was
further purified in a 300,000 MWCO spin column (Sartorius) with three 500-μL washes in
1x NEBuffer 3. 125 ng pre-selection library was digested for 30 min at 37 °C in 1x
NEBuffer 3 with a total 24 μL of fresh in vitro transcribed/translated TALENs and empty
lysate. For all CCR5A and ATM TALENs, 6 μL of in vitro transcription/translation left
TALEN and 6 μL of right TALEN were used, corresponding to a final concentration in a
cleavage reaction of 16 nM ± 2 nM or 12 nM ± 1.5 nM for CC5A or ATM TALENs,
respectively. These TALEN concentrations were quantified by Western blot performed in
parallel with digestion.
For all selections, the TALEN-digested library was incubated with 1 μL of 100 μg/μL RNase
A (Qiagen) for 2 min and then Q-column purified. 50 μL of purified DNA was incubated
with 3 μL of 10 mM dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM dGTP, 10 mM dTTP)
(NEB), 6 μL of 10x NEBuffer 2, and 1 μL of 5 U/μL Klenow Fragment DNA Polymerase
(NEB) for 30 min at room temperature and Q-column purified. 50 μL of the eluted DNA
was ligated with 2 pmol of heated and cooled #1 adapters containing barcodes
corresponding to each sample (selections with different TALEN concentrations or
constructs) (Supplementary Table S12A). Ligation was performed in 1x T4 DNA Ligase
Buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM DTT, pH 7.5) with 1 μL of
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t400 U/μL T4 DNA ligase (NEB) in 60 μL total volume for 16 h at room temperature, then
Q-column purified.
6 μL of the eluted DNA was amplified by PCR in 150 μL total reaction volume (divided into
3x 50 μL reactions) for 14 to 22 cycles using the #2A adapter primers in Supplementary
Table S12A. The PCR products were purified by Q-column. Each DNA sample was
quantified with Quant-iT™ PicoGreen® dsDNA Kit (Invitrogen) and then pooled into an
equimolar mixture. 500 ng of pooled DNA was run a 5% TBE 18-well Criterion PAGE gel
(BioRad) for 30 min at 200 V and DNAs of length ~230 bp (corresponding to 1.5 target site
repeats plus adapter sequences) were isolated and purified by Q-column. ~2 ng of eluted
DNA was amplified by PCR for 5 to 8 cycles with #2B adapter primers (Supplementary
Table S12A) and purified by M-column.
10 μL of eluted DNA was purified using 12 μL of AMPure XP beads (Agencourt) and
quantified with an Illumina/Universal Library Quantification Kit (Kapa Biosystems). DNA
was prepared for high-throughput DNA sequencing according to Illumina instructions and
sequenced using a MiSeq DNA Sequencer (Illumina) using a 12 pM final solution and 156-
bp paired-end reads. To prepare the preselection library for sequencing, the pre-selection
library was digested with 1 μL to 4 μL of appropriate restriction enzyme (CCR5A = Tsp45I,
ATM = Acc65I, CCR5B = AvaI (NEB)) for 1 h at 37 °C then ligated as described above
with 2 pmol of heated and cooled #1 library adapters (Supplementary Table S9A). Pre-
selection library DNA was prepared as described above using #2A library adapter primers
and #2B library adapter primers in place of #2A adapter primers and #2B adapter primers,
respectively (Supplementary Table S12A). The resulting pre-selection library DNA was
sequenced together with the TALEN-digested samples.
Discrete In Vitro TALEN Cleavage Assays
Discrete DNA substrates for TALEN digestion were constructed by combining pairs of
oligonucleotides as specified in Supplementary Table 12B with restriction cloning22 into
pUC19 (NEB). Corresponding cloned plasmids were amplified by PCR (59 °C annealing for
15 s) for 24 cycles with pUC19Ofwd and pUC19Orev primers (Supplementary Table S12B)
and Q-column purified. 50 ng of amplified DNAs were digested in 1x NEBuffer 3 with 3 μL
each of in vitro transcribed/translated TALEN left and right monomers (corresponding to a
~16 nM to ~12 nM final TALEN concentration), and 6 μL of empty lysate in a total reaction
volume of 120 μL. The digestion reaction was incubated for 30 min at 37 °C, then incubated
with 1 μL of 100 μg/μL RNase A (Qiagen) for 2 min and purified by M-column. The entire
10 μL of eluted DNA with glycerol added to 15% was analyzed on a 5% TBE 18-well
Criterion PAGE gel (Bio-Rad) for 45 min at 200 V, then stained with 1x SYBR Gold
(Invitrogen) for 10 min. Bands were visualized and quantified on an AlphaImager HP
(Alpha Innotech).
Cellular TALEN Cleavage Assays
TALENs were cloned into mammalian expression vectors12 and the resulting TALEN
vectors transfected into U2OS-EGFP cells as previously described.12 Genomic DNA was
isolated after 2 days as previously described.12 For each assay, 50 ng of isolated genomic
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tDNA was amplified by PCR [98 °C, 15 s 67.5 °C, 15 s; 72 °C, 22s] for 35 cycles with pairs
of primers with or without 4% DMSO as specified in Supplementary Table S12C. Two PCR
reactions were performed for OffC-5 to improve the limit of detection. The relative dsDNA
content of the PCR reaction for each genomic site was quantified with Quant-iT™
PicoGreen ® dsDNA Kit (Invitrogen) and then pooled into an equimolar mixture, keeping
no-TALEN and all TALEN-treated samples separate. DNA corresponding to 150 to 350 bp
was purified by PAGE as described above.
44 μL of eluted DNA was incubated with 5 μL of 1x T4 DNA Ligase Buffer and 1 μL of 10
U/μL Polynucleotide kinase (NEB) for 30 min at 37 °C and Q-column purified. 43 μL of
eluted DNA was incubated with 1 μL of 10 mM dATP (NEB), 5 μL of 10x NEBuffer 2, and
1 μL of 5 U/μL DNA Klenow Fragment (3′ → 5′ exo−) (NEB) for 30 min at 37 °C and
purified by M-column. 10μL of eluted DNA was ligated as above with 10 pmol of heated
and cooled G (genomic) adapters (Supplementary Table S12A) and purified by Q-column. 8
μL of eluted DNA was amplified by PCR for 6 to 8 cycles with G-B primers containing
barcodes corresponding to each sample. Each sample DNA was quantified with Quant-iT™
PicoGreen ® dsDNA Kit (Invitrogen) and then pooled into an equimolar mixture. The
combined DNA was subjected to high-throughput sequencing using a MiSeq as described
above.
Data Analysis
Illumina sequencing reads were filtered and parsed with scripts written in Unix Bash as
outlined in the Supplementary Algorithms. DNA sequences and source code are available
upon request. Specificity scores were calculated as previously described.22 Sample sizes for
sequencing experiments were maximized (within practical experimental considerations) to
ensure greatest power to detect effects. Statistical analysis on the distribution of number of
mutations in various TALEN selections in Supplementary Table S2 was performed as
previously described22. Statistical analysis of TALEN modified genomic sites in
Supplementary Tables S7, S8 and S9 was performed as previously described25 with multiple
comparison correction using the Benjamini-Hochberg method.37, 38
To determine extrapolated mean enrichment curves mutation enrichment value as function
of mutation number were fit to an exponential function, a*eb, with R2 reported utilizing the
non-linear least squares method. The a, b and R2 values and the mutation range for these fits
are reported in Supplementary Table S11. These exponential decrease, b, were used to
extrapolate all mean enrichment values beyond five mutations to determine the extrapolated
mean enrichment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. TALEN architecture and selection scheme
(A) Architecture of a TALEN. A TALEN monomer contains an N-terminal domain (blue) followed by an array of TALE repeats
(brown), a C-terminal domain (green), and a FokI nuclease cleavage domain (purple). The 12th and 13th amino acids (the RVD,
red) of each TALE repeat recognize a specific DNA base pair. Two different TALENs bind their corresponding half-sites,
allowing FokI dimerization and DNA cleavage. The C-terminal domain variants used in this study are shown in green. (B) A
single-stranded library of DNA oligonucleotides containing partially randomized left half-site (L), spacer (S), right half-site (R)
and constant region (thick black line) was circularized, then concatemerized by rolling circle amplification. The concatemerized
double stranded DNA (double arrows) contained repeated target sites with L′ S′ R′ representing the reverse sequence
complement of L S R. (C) The concatemerized DNA libraries of mutant target sites were incubated with an in vitro-translated
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tTALEN of interest. Cleaved library members were blunted and ligated to adapter #1. The ligation products were amplified by
PCR using one primer consisting of adapter #1 and the other primer consisting of adapter #2–constant sequence, which anneals
to the constant regions. From the resulting ladder of amplicons containing a half-site with an integral number (n) of repeats of a
target site (represented by brackets), amplicons corresponding to 1.5 target-sites in length were isolated by gel purification and
subjected to high-throughput DNA sequencing and computational analysis (Supplementary Algorithms).
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tFigure 2. In vitro selection results
The fraction of sequences surviving selection (green) and before selection (black) are shown for CCR5A TALENs (A) and ATM
TALENs (B) with EL/KK FokI domains as a function of the number of mutations in both half-sites (left and right half-sites
combined excluding the spacer). (C) Specificity scores for the CCR5A TALENs at all positions in the target half-sites plus a
single flanking position. The colors range from dark blue (maximum specificity score of 1.0) to white (no specificity, score of 0)
to dark red (maximum negative score of −1.0); see the main text for details. Boxed bases represent the intended target base.
Note for the right half-site, the R18 TALENs, the sense strand is shown. (D) Same as (C) for the ATM TALENs. For (A), (B),
(C) and (D) sample statistics (sample sizes, means, standard deviations, and P-values) are given in Supplementary Table S2 and
S3. (E) Enrichment values from the selection of L13+R13 CCR5B TALEN for 16 mutant DNA sequences (mutations in red)
relative to on-target DNA (OnB). (F) Correspondence between discrete in vitro TALEN cleavage efficiency (cleaved DNA as a
fraction of total DNA) for the sequences listed in (E) normalized to on-target cleavage (= 1) versus their enrichment values in
the selection normalized to the on-target enrichment value (= 1). The Pearson’s r coefficient of correlation between normalized
cleavage efficiency and normalized enrichment value is 0.90. (G) Discrete assays of on-target and off-target sequences used in
(F) as analyzed by PAGE.
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tFigure 3. Cellular modification induced by TALENs at on-target and predicted off-target genomic sites
(A) For cells treated with either no TALEN or CCR5A TALENs containing heterodimeric EL/KK, heterodimeric ELD/KKR, or
the homodimeric (Homo) FokI cleavage domain variants, cellular modification rates are shown as the percentage of observed
insertions or deletions (indels) consistent with TALEN cleavage relative to the total number of sequences for on-target (On) and
predicted off-target sites (Off). See the main text for details. ND refers to no data collected since the cellular modification of off-
target sites OffC-38, OffC-49, OffC-69 and OffC-76 was not assayed for CCR5A TALENs containing EL/KK and ELD/KKR
FokI domains. (B) Same as (A) for ATM TALENs. For (A) and (B) sample sizes and P-values are given in Supplementary
Tables S7 and S9.
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tFigure 4. In vitro specificity as a function of TALEN length
The enrichment value of on-target (zero mutation) and off-target sequences containing one to six mutations are shown for
CCR5B TALENs of varying TALE repeat array lengths with EL/KK FokI domains. The TALENs targeted DNA sites of 32 bp
(L16+R16), 29 bp (L16+R13 or L13+R16), 26 bp (L16+R10 or L13+R13 or L10+R16), 23 bp (L13+R10 or L10+R13) or 20 bp
(L10+R10) in length.
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tFigure 5. In vitro specificity and discrete cleavage efficiencies of TALENs containing canonical or engineered C-terminal domains
(A and B) On-target enrichment values for selections of (A) CCR5A TALENs containing canonical, Q3, Q7, or 28-aa C-
terminal domains with EL/KK FokI cleavage domains or (B) ATM TALENs containing canonical, Q3 or Q7 C-terminal
domains with EL/KK FokI cleavage domains. (C) CCR5A on-target sequence (OnC) and double-mutant sequences with
mutations in red. For CCR5A, sequences containing two mutations were assayed because one-mutation and zero-mutation
sequences were similarly enriched (Supplementary Table S4A). (D) ATM on-target sequence (OnA), single-mutant sequences,
and double-mutant sequences with mutations in red. (E) Discrete in vitro cleavage efficiency of DNA sequences listed in (C)
with CCR5A TALENs containing either canonical or engineered Q7 C-terminal domains with EL/KK FokI domains. Error bars
reflect s.d. from three biological replicates, except two replicates for C4. All pairwise P-values were calculated between the
cleavage efficiencies of the on-target sequence (OnC) digested by CCR5A TALENs containing the canonical C-terminal vs. the
cleavage efficiencies of a mutant sequence (C1, C2, …., or C8) digested by CCR5A TALENs containing the canonical C-
terminal domain. All pairwise P-values were also calculated between the cleavage efficiencies of the on-target sequence (OnC)
digested by CCR5A TALENs containing the Q7 C-terminal domain vs. the cleavage efficiencies of a mutant sequence (C1, C2,
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t…., or C8) digested by CCR5A TALENs containing the Q7 C-terminal domain. The cleavage efficiencies of mutant sequences
C1, C2, C6, C7 and C8 digested by CCR5A TALENs containing the canonical C-terminal domain demonstrate a P-value
significantly different (P-value < 0.025) from the cleavage efficiencies of the on-target sequence (OnC) digested by CCR5A
TALENs containing the canonical C-terminal domain. The cleavage efficiencies of mutant sequences C1, C3, C4, C6, C7 and
C8 digested by CCR5A TALENs containing the Q7 C-terminal domain demonstrate a P-value significantly different (P-value <
0.025) from the cleavage efficiencies of the on-target sequence (OnC) digested by CCR5A TALENs containing the Q7 C-
terminal domain. (F) Same as (E) for ATM TALENs. The cleavage efficiencies of mutant sequences A1, A2, A3, A5, A6, A7
and A8 digested by ATM TALENs containing the Q7 C-terminal domain demonstrate a P-value significantly different (P-value
< 0.025) from the cleavage efficiencies of ATM TALENs containing the canonical C-terminal domain digestion of the on-target
sequence (OnC).
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tFigure 6. Specificity of engineered TALENs in human cells
(A) The cellular modification efficiency of canonical and engineered TALENs expressed as a percentage of indels consistent
with TALEN-induced modification out of total sequences is shown for the on-target CCR5A site (OnCCR5A) and for CCR5A
off-target site #5 (OffC5), the most highly cleaved off-target substrate tested. All pairwise P-values comparing the number of
observed sequences containing insertions or deletions consistent with TALEN-induced cleavage vs. the total number of
sequences were calculated with a Fischer exact test between samples (see Supplementary Table S7). P-values are < 0.005 for
samples of canonical vs. Q3 vs. Q7 TALENs in the same FokI background for both on-target and off-target sites with the
exception of off-target site #5 modified with Q3 vs. Q7 TALENs in the EL/KK FokI background (P-value < 0.087). On:off
target activity, defined as the ratio of on-target to off-target modification, is shown above each pair of bars. (B) The on:off target
activity of the canonical, Q3, and Q7 TALENs for each detected genomic off-target substrate of the CCR5A TALEN with the
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tELD/KKR FokI domain are shown. The absolute genomic modification frequency for the on-target site is in parentheses. (C)
Same as (B) for the ATM TALENs and off-target sites. (D) The on:off target activities of the canonical, Q3, and Q7 TALENs
for each detected genomic off-target substrate of the PMS2, SDHD, and HDAC1 TALENs with the ELD/KKR FokI domain are
shown. The absolute genome modification frequency for the on-target site is in parentheses.
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